Scholarlink

Purpose <p>To investigate MRI features associated with <i>KRAS</i> mutation status in PDAC and their clinical implications.</p> Materials and methods <p>In our study, 1474 patients pathologically confirmed PDAC patients between January 2016 and December 2023 were evaluated. Patients with genetic testing (<i>KRAS</i> mutation status) and MRI examination were enrolled and grouped as <i>KRAS</i>-mutated PDAC and non-<i>KRAS</i>-mutated PDAC. Contrast-enhanced MRI features, clinicopathologic findings, and prognosis were compared between two groups.</p> Results <p>A total of 308 surgically confirmed PDAC patients (median age, 67 years [IQR, 59, 72]; 183 male and 125 female) with genetic testing data were included, of which 258 had KRAS-mutated PDAC and 50 had non-KRAS-mutated PDAC. KRAS-mutated PDAC demonstrated distinct clinicopathological characteristics, including higher rates of diabetes (OR, 2.450, 95% CI, 1.151–5.212, <i>P</i> = 0.020), pathological peripheral nerve infiltration (OR, 2.296, 95% CI, 1.083–4.867, <i>P</i> = 0.030), and pN stage (OR, 2.006, 95% CI, 1.012–3.976, <i>P</i> = 0.046). The 1-, 3-, 5-year OS rate was worse for <i>KRAS</i>-mutated PDAC (89.9%, 45.4%, 23.2% vs. 95.1%, 60.4% 60.4%, <i>P</i> = 0.045). Rim enhancement (OR = 2.039, 95% CI: 1.053, 3.951, <i>P</i> = 0.035) and larger tumor size (OR = 3.286, 95% CI: 1.523, 7.089, <i>P</i> = 0.002) were identified as distinctive MRI features for <i>KRAS</i>-mutated PDAC.</p> Conclusion <p><i>KRAS</i>-mutated PDAC presents unique clinical and pathological features and is associated with poorer prognosis. Rim enhancement and larger tumor size on MRI were identified as features associated with KRAS-mutated PDAC.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma

  • 期刊论文

  • 发表日期：

    2025年3月29日

查看全文
  • Junjian Shen,
  • Xingxing Wang,
  • Keqin Yu,
  • Kai Liu,
  • Xiaolin Wang,
  • Haitao Sun,
  • Jianjun Zhou,
  • Mengsu Zeng

摘要

Purpose

To investigate MRI features associated with KRAS mutation status in PDAC and their clinical implications.

Materials and methods

In our study, 1474 patients pathologically confirmed PDAC patients between January 2016 and December 2023 were evaluated. Patients with genetic testing (KRAS mutation status) and MRI examination were enrolled and grouped as KRAS-mutated PDAC and non-KRAS-mutated PDAC. Contrast-enhanced MRI features, clinicopathologic findings, and prognosis were compared between two groups.

Results

A total of 308 surgically confirmed PDAC patients (median age, 67 years [IQR, 59, 72]; 183 male and 125 female) with genetic testing data were included, of which 258 had KRAS-mutated PDAC and 50 had non-KRAS-mutated PDAC. KRAS-mutated PDAC demonstrated distinct clinicopathological characteristics, including higher rates of diabetes (OR, 2.450, 95% CI, 1.151–5.212, P = 0.020), pathological peripheral nerve infiltration (OR, 2.296, 95% CI, 1.083–4.867, P = 0.030), and pN stage (OR, 2.006, 95% CI, 1.012–3.976, P = 0.046). The 1-, 3-, 5-year OS rate was worse for KRAS-mutated PDAC (89.9%, 45.4%, 23.2% vs. 95.1%, 60.4% 60.4%, P = 0.045). Rim enhancement (OR = 2.039, 95% CI: 1.053, 3.951, P = 0.035) and larger tumor size (OR = 3.286, 95% CI: 1.523, 7.089, P = 0.002) were identified as distinctive MRI features for KRAS-mutated PDAC.

Conclusion

KRAS-mutated PDAC presents unique clinical and pathological features and is associated with poorer prognosis. Rim enhancement and larger tumor size on MRI were identified as features associated with KRAS-mutated PDAC.

Graphical abstract